 Shares of Vaxcyte Inc. PCVX, -7.42 soared 46.7 in premarket trading on Monday after the company said its experimental 24-valent pneumococcal conjugate vaccine met the primary endpoint in a Phase 12 clinical proof-of-concept study. The vaccine was tested in healthy adults. 